WeTrials
Recruiting

A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)

What is this study?

This study looks at whether we can safely reduce extra treatments, like radiation, for certain early-stage uterine cancers based on the specific genetic features of the tumor. By tailoring the care, the study aims to protect patients from unnecessary side effects while keeping them healthy.

Who can participate?

You may be able to join if you are 18 or older, have had surgery to remove early-stage cancer of the uterine lining with no visible cancer left behind, and are generally well enough to do daily activities. Certain prior treatments, like past pelvic radiation, mean you cannot join.

What will happen?

Depending on your specific cancer's genetic profile, you might receive localized radiation therapy, such as vaginal brachytherapy, or you might just be closely monitored with regular check-ups without active treatment right away. Your care team will guide you through your specific path.

Where and when?

This study is currently recruiting participants at multiple locations across the United States, including sites in Alaska, Arizona, and California.

Key Points
  • 1Tests tailored treatments based on your tumor's specific genetic profile.
  • 2May help some patients safely avoid unnecessary radiation or treatments.
  • 3Currently actively recruiting participants at various locations in the U.S.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Endometrial Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.